Resources
Life Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.
Life Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS IVA for the first time, or after a break.
Life Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Guidelines
These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type IVA (MPS IVA) under the Life Saving Drugs Program.
Life Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS IVA.
Dedication Ceremony for the National Site of Recognition for Thalidomide and their Families – Program Booklet
The National Site of Recognition was dedicated by the Minister for Health and Aged Care, along with thalidomide survivors and their families, on 30 November 2023. This is the program booklet from the ceremony.
National Governance Framework for Cancer and Population Screening
The National Governance Framework for Cancer and Population Screening outlines the governance arrangements of our various committees and groups.
Invasive Group A Streptococcal (iGAS) Disease – CDNA National guidelines for Public Health Units
These guidelines outline Australia’s national minimum standard for surveillance, laboratory testing, case management and contact management for Invasive Group A Streptococcal (iGAS) disease.
National Site of Recognition Steering Committee communique – September 2023
Details of the sixth meeting of Steering Committee for the National Site of Recognition for thalidomide survivors and their families.
Life Saving Drugs Program – Late infantile Batten disease (CLN2 disease) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Batten disease.
Life Saving Drugs Program – Fabry disease – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Fabry disease.
Life Saving Drugs Program – Pompe disease – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Pompe disease for the first time, or after a break.
Life Saving Drugs Program – Gaucher disease (type 1) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Gaucher disease.
Life Saving Drugs Program – Pompe disease – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Pompe disease.
Life Saving Drugs Program – Late infantile Batten disease (CLN2 disease) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Batten disease for the first time, or after a break.
Life Saving Drugs Program – Fabry disease – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Fabry disease for the first time, or after a break.
Advisory Committee for the COVID-19 Response for People with Disability – Summary of outcomes 3 October 2023
This communique provides a summary of the advisory committee's meeting on 3 October 2023.
Application Form A for Conditions Group 1 – Inborn Errors of Metabolism
Application for Australian Government financial assistance for individuals with Inborn Errors of Metabolism — DHPR, hyperphenylalaninemia and PKU conditions only. For other conditions, use Application Form B.
Application Form C – Change of details – Inborn Errors of Metabolism
Individuals registered with the Inborn Errors of Metabolism program can use this form to change their personal information.
Application Form B for Conditions other than Group 1 – Inborn Errors of Metabolism
Application for Australian Government financial assistance for individuals with Inborn Errors of Metabolism (other than DHPR, hyperphenylalaninemia and PKU).
Application to register as an Approved Metabolic Specialist – Inborn Errors of Metabolism
Specialist doctors can use this form to apply for registration as an approved metabolic specialist under the Inborn Errors of Metabolism (IEM) program.
National Strategy for Health Practitioner Pain Management Education
The National Pain Management Health Practitioner Education Strategy was launched on 6 October 2023. The strategy was developed by the Faculty of Pain Medicine (FPM), Australian and New Zealand College of Anaesthetists (ANZCA) with funding from the Australian Government.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 20 October 2023
Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 16th meeting on 20 October 2023.
Advisory Committee for the COVID-19 Response for People with Disability – Summary of outcomes 23 August 2023
This communique provides a summary of the advisory committee's meeting on 23 August 2023.
National Site of Recognition Steering Committee communique – 10 July 2023
Details of the fifth meeting of Steering Committee for the National Site of Recognition for thalidomide survivors and their families, held on 10 July 2023.
Advisory Committee for the COVID-19 Response for People with Disability – Summary of outcomes 21 July 2023
This communique provides a summary of the advisory committee's meeting on 21 July 2023.
Date last updated: